Antidiabetic drug administration prevents bone mineral density loss: Evidence from a two-sample Mendelian randomization study

PLoS One. 2024 Mar 7;19(3):e0300009. doi: 10.1371/journal.pone.0300009. eCollection 2024.

Abstract

The aim of this study was to investigate the effect of common antidiabetic drugs on BMD by two-sample Mendelian randomization (MR). The single nucleotide polymorphisms that were strongly associated with insulin, metformin, rosiglitazone and gliclazide were extracted as instrumental variables (IVs) for MR analysis. The inverse variance weighted (IVW) method was used as the primary MR method to assess the causal effect of antidiabetic drugs on BMD, and other MR methods, including Weighted median, MR Egger and Weighted mode, were used for complementary analysis. Reliability and stability were assessed by the leave-one-out test. In the present work, IVW estimation of the causal effect of insulin on heel BMD demonstrated that there was a null effect of insulin on heel BMD (β = 0.765; se = 0.971; P = 0.430), while metformin treatment had a positive effect on heel BMD (β = 1.414; se = 0.460; P = 2.118*10-3). The causal relationship between rosiglitazone and heel BMD analysed by IVW suggested that there was a null effect of rosiglitazone on heel BMD (β = -0.526; se = 1.744; P = 0.763), but the causal effect of gliclazide on heel BMD evaluated by IVW demonstrated that there was a positive effect of gliclazide on heel BMD (β = 2.671; se = 1.340; P = 0.046). In summary, the present work showed that metformin and gliclazide have a role in reducing BMD loss in patients with diabetes and are recommended for BMD loss prevention in diabetes.

MeSH terms

  • Bone Density / genetics
  • Diabetes Mellitus*
  • Genome-Wide Association Study
  • Gliclazide* / pharmacology
  • Gliclazide* / therapeutic use
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use
  • Insulin
  • Insulin, Regular, Human
  • Mendelian Randomization Analysis
  • Metformin* / pharmacology
  • Metformin* / therapeutic use
  • Polymorphism, Single Nucleotide
  • Reproducibility of Results
  • Rosiglitazone

Substances

  • Gliclazide
  • Hypoglycemic Agents
  • Insulin
  • Insulin, Regular, Human
  • Metformin
  • Rosiglitazone

Grants and funding

This study was supported by the Quanzhou Guiding Science and Technology Project (2021N130S); the Natural Science Foundation of Fujian Province (2022J011457) and Quanzhou Science and Technology Plan Project (2021N061S). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.